William BASc - NervGen Pharma Interim CoFounder

All Insiders . USA . 
Stock . NervGen Pharma Corp . Stakeholders . Insider . William BASc
NGENF Stock  USD 1.88  0.02  1.05%   

Insider

William BASc is Interim CoFounder of NervGen Pharma Corp
Age 60
Phone778 731 1711
Webhttps://www.nervgen.com

NervGen Pharma Management Efficiency

The company has return on total asset (ROA) of (0.6661) % which means that it has lost $0.6661 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.4176) %, meaning that it generated substantial loss on money invested by shareholders. NervGen Pharma's management efficiency ratios could be used to measure how well NervGen Pharma manages its routine affairs as well as how well it operates its assets and liabilities.
NervGen Pharma Corp has accumulated 324.69 K in total debt with debt to equity ratio (D/E) of 0.03, which may suggest the company is not taking enough advantage from borrowing. NervGen Pharma Corp has a current ratio of 4.17, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist NervGen Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, NervGen Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like NervGen Pharma Corp sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for NervGen to invest in growth at high rates of return. When we think about NervGen Pharma's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

David JacobsteinBroadstone Net Lease
74
Michael CokeBroadstone Net Lease
53
Tomasz KulaTscan Therapeutics
N/A
Roderick PickneyBroadstone Net Lease
45
Jason TreftMerit Medical Systems
N/A
Shekar NarasimhanBroadstone Net Lease
67
Carole BurnellSonida Senior Living
51
Denise BrooksWilliamsBroadstone Net Lease
53
Stephen ElledgeTscan Therapeutics
N/A
Michel VoigtMerit Medical Systems
52
Jeremy FalkeSonida Senior Living
51
Dale ConnorLend Lease Group
N/A
Benjamin HarrisSonida Senior Living
43
Stephen HauptBroadstone Net Lease
63
Jeffrey CellucciSonida Senior Living
32
Robert HollisterSonida Senior Living
64
Jay ReedSonida Senior Living
N/A
Eric MDAcumen Pharmaceuticals
69
CPA CPASonida Senior Living
N/A
Joseph PierceMerit Medical Systems
N/A
David BrickmanSonida Senior Living
66
NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. NervGen Pharma Corp. was incorporated in 2017 and is based in Vancouver, Canada. NERVGEN PHARMA operates under Biotechnology classification in the United States and is traded on OTC Exchange. NervGen Pharma Corp [NGENF] is traded as part of a regulated electronic over-the-counter service offered by the NASD.

Management Performance

Return On Equity-1.42
Return On Asset-0.67

NervGen Pharma Corp Leadership Team

Elected by the shareholders, the NervGen Pharma's board of directors comprises two types of representatives: NervGen Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NervGen. The board's role is to monitor NervGen Pharma's management team and ensure that shareholders' interests are well served. NervGen Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, NervGen Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
Brian McAlister, CoFounder Advisor
Harold DMD, CoFounder Director
Adam MD, Interim Director
William BASc, Interim CoFounder

NervGen Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is NervGen Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-1.42
Return On Asset-0.67
Current Valuation48.78 M
Shares Outstanding58.68 M
Shares Owned By Insiders25.27 %
Price To Book5.13 X
EBITDA(11.33 M)
Net Income(12.73 M)
Cash And Equivalents11.65 M
Cash Per Share0.20 X

Currently Active Assets on Macroaxis

VVisa Class A
SSentinelOne
GMGeneral Motors
MSFTMicrosoft
FFord Motor

Other Information on Investing in NervGen OTC Stock

NervGen Pharma financial ratios help investors to determine whether NervGen OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in NervGen with respect to the benefits of owning NervGen Pharma security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY